IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

In the realm of diabetes management and diagnosis, two tests often come into focus: the fasting glucose test and the A1c test. Both are crucial tools in assessing blood sugar levels, but they serve ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Dr. Soma Mandal, a board-certified internist at Summit Health in New Providence, New Jersey, says that getting a CBC test is ...

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...